drugset / Trial / NCT02825563

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

NCT02825563

Phase 1 Completed 22 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to further study the pharmacokinetic characteristics of Anlotinib in Advanced Cancer Patients with High Fat Diet.

Timeline

Start
2016-06
Primary completion
2018-08-15
Completion
2018-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule Other

Indications

No indication recorded.